Latest filing published 29 May 2009 for Molecular Insight Pharmaceuticals, Inc., €16k.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Norman D. LaFrance: trading record in brief
Norman D. LaFrance discloses dealings in Molecular Insight Pharmaceuticals, Inc. to SEC (Form 4). In total, 6 filings cover trades dated from 29 November 2007 to 28 May 2009.
The open-market side counts 4 purchases for €23k alongside 1 sale for €16k. Taken together, the purchases exceed the sales by €6,665. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. So far in 2009, the count stands at no purchases and 1 sale.
A typical purchase (the median) is worth €5,479.
The newest entry dates from 29 May 2009: an open-market sale of €16k, in Molecular Insight Pharmaceuticals, Inc. The last insider purchase was made public on 4 December 2007, 6,915 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Norman D. LaFrance
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,093 shares@ US$3.76Common StockSEC:0001209191-09-029560:0
- 18,750 shares@ US$0.01Common StockSEC:0001209191-08-032471:0
- 100 shares@ US$8.75Common StockSEC:0001209191-07-067599:0Canonical exit: 28 Feb 2008 (T+90)
- 1,900 shares@ US$8.78Common StockSEC:0001209191-07-067599:1Canonical exit: 28 Feb 2008 (T+90)
- 100 shares@ US$7.95Common StockSEC:0001209191-07-067023:0Canonical exit: 27 Feb 2008 (T+90)
- 1,900 shares@ US$8.05Common StockSEC:0001209191-07-067023:1Canonical exit: 27 Feb 2008 (T+90)
6 of 6 declarations
